Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2018 | Pre-clinical activity of tipifarnib in CTCL

Pierluigi Porcu • 12 Sep 2018

SOHO 2018

Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Tipifarnib

Providing us with insight into a trial not yet published, Pierluigi Porcu, MD, from Jefferson Hospital, Sidney Kimmel Cancer Center, Philadelphia, PN, discusses his team’s investigation into potential molecular biomarkers of response in mice induced to overexpress cytokine IL-15. Dr Porcu uses tipifarnib, a farnesyltransferase inhibitor which targets the RAS pathway, to treat the induced cutaneous T-cell lymphoma developed in the mice. Currently, he is focusing on looking for biomarkers of response from these animal trials. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX

Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD

Pierluigi Porcu • 16 Jun 2023

The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges

Pierluigi Porcu • 16 Jun 2023

Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial

Pierluigi Porcu • 16 Jun 2023

Nanatinostat and valganciclovir for EBV-associated lymphoma

Pierluigi Porcu • 6 Dec 2020

Related Videos

Molecular characteristics associated with increased risk of disease progression in SMM

Mark Bustoros • 27 Sep 2023

Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia

Mark Bustoros • 27 Sep 2023

Using lineage tracing to define responding CAR T-cells in patients with LBCL

Zinaida Good • 9 Apr 2024

Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis

Marco Ruella • 9 Apr 2024